SEHK:2393

Stock Analysis Report

Yestar Healthcare Holdings

Executive Summary

Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products; distribution of in vitro diagnostic products; and manufacture and sale of dental films in the People’s Republic of China.

Snowflake

Fundamentals

Fair value with acceptable track record.

Share Price & News

How has Yestar Healthcare Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.4%

2393

1.3%

HK Medical Equipment

2.2%

HK Market


1 Year Return

-35.0%

2393

8.1%

HK Medical Equipment

-1.3%

HK Market

Return vs Industry: 2393 underperformed the Hong Kong Medical Equipment industry which returned 8.1% over the past year.

Return vs Market: 2393 underperformed the Hong Kong Market which returned -1.3% over the past year.


Share holder returns

2393IndustryMarket
7 Day-3.4%1.3%2.2%
30 Day0.7%-1.0%-2.9%
90 Day24.8%19.0%-5.8%
1 Year-35.0%-35.0%9.3%8.1%2.3%-1.3%
3 Year-67.3%-68.3%10.9%7.5%15.6%3.9%
5 Year-36.0%-39.3%3.3%-1.8%20.1%0.06%

Price Volatility Vs. Market

How volatile is Yestar Healthcare Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Yestar Healthcare Holdings undervalued based on future cash flows and its price relative to the stock market?

49%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Undervalued: 2393 (HK$1.41) is trading below our estimate of fair value (HK$2.74)

Significantly Undervalued: 2393 is trading below fair value by more than 20%.


Price Based on Earnings

PE vs Industry: 2393 is good value based on its PE Ratio (10.6x) compared to the Medical Equipment industry average (15.7x).

PE vs Market: 2393 is poor value based on its PE Ratio (10.6x) compared to the Hong Kong market (10.3x).


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate 2393's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: 2393 is overvalued based on its PB Ratio (2.6x) compared to the HK Medical Equipment industry average (1.6x).


Next Steps

Future Growth

How is Yestar Healthcare Holdings expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

11.3%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: Insufficient data to determine if 2393's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if 2393's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 2393's revenue (11.3% per year) is forecast to grow faster than the Hong Kong market (10.1% per year).

High Growth Revenue: 2393's revenue (11.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: 2393's Return on Equity is forecast to be high in 3 years time (27.4%)


Next Steps

Past Performance

How has Yestar Healthcare Holdings performed over the past 5 years?

20.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 2393's earnings have grown significantly by 20.7% per year over the past 5 years.

Accelerating Growth: 2393's earnings growth over the past year (5.4%) is below its 5-year average (20.7% per year).

Earnings vs Industry: 2393 earnings growth over the past year (5.4%) underperformed the Medical Equipment industry 50.2%.


Return on Equity

High ROE: Whilst 2393's Return on Equity (32.55%) is high, this metric is skewed due to their high level of debt.


Return on Assets

ROA vs Industry: 2393 has a higher Return on Assets than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: 2393 has improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Yestar Healthcare Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 2393's short term assets (CN¥3.2B) exceeds its short term liabilities (CN¥2.9B)

Long Term Liabilities: 2393's short term assets (3.2B) exceeds its long term liabilities (1.8B)


Debt to Equity History and Analysis

Debt Level: 2393's debt to equity ratio (148.8%) is considered high

Reducing Debt: 2393's debt to equity ratio has increased from 22.7% to 148.8% over the past 5 years.

Debt Coverage: 2393's debt is not well covered by operating cash flow (19.2%).

Interest Coverage: 2393's interest payments on its debt are well covered by EBIT (5.6x coverage).


Balance Sheet

Inventory Level: 2393 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 2393's debt is covered by short term assets (assets are 1.824940x debt).


Next Steps

Dividend

What is Yestar Healthcare Holdings's current dividend yield, its reliability and sustainability?

5.00%

Expected Dividend Yield


Dividend Yield vs Market

company0%marketbottom25%2.3%markettop25%6.3%industryaverage1.6%forecastin3Years5.0%

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate 2393's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2393's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 2393's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2393's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 2393 is not paying a notable dividend for .


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2393's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

What is the CEO of Yestar Healthcare Holdings's salary, the management and board of directors tenure and is there insider trading?

4.2yrs

Average management tenure


CEO

James Hartono (43yo)

0yrs

Tenure

CN¥4,372,000

Compensation

Mr. James Hartono serves as the Chairman of The Board and Chief Executive Officer of Yestar International Holdings Company Limited. Mr. Hartono has over 12 years of experience in the distribution of image  ...


CEO Compensation Analysis

Compensation vs. Market: James's total compensation ($USD616.81K) is about average for companies of similar size in the Hong Kong market ($USD302.46K).

Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.2yrs

Average Tenure

44.5yo

Average Age

Experienced Management: 2393's management team is considered experienced (4.2 years average tenure).


Board Age and Tenure

6.1yrs

Average Tenure

49.5yo

Average Age

Experienced Board: 2393's board of directors are considered experienced (6.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellCN¥72,224,81512 Jul 19
Jeane Hartono
EntityIndividual
Shares67,500,000
Max PriceCN¥1.07
BuyCN¥72,224,81512 Jul 19
James Hartono
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares67,500,000
Max PriceCN¥1.07
BuyCN¥411,699,95706 Feb 19
FUJIFILM Holdings Corporation
EntityCompany
Shares230,000,000
Max PriceCN¥1.79

Ownership Breakdown


Management Team

  • James Hartono (43yo)

    Chairman & CEO

    • Tenure: 0yrs
    • Compensation: CN¥4.37m
  • Ying Wang (58yo)

    Executive Director

    • Tenure: 6.7yrs
    • Compensation: CN¥2.00m
  • To Chan (60yo)

    Executive Director

    • Tenure: 7.7yrs
    • Compensation: CN¥1.89m
  • Hong Wang (44yo)

    CFO & Executive Director

    • Tenure: 7.7yrs
    • Compensation: CN¥988.00k
  • Ivan Ng (46yo)

    Company Secretary

    • Tenure: 4.4yrs
  • Chung Chan (43yo)

    COO & Executive Director

    • Tenure: 3.8yrs
    • Compensation: CN¥2.28m
  • Changxiang Liao (44yo)

    GM of Yestar Technology

    • Tenure: 0yrs
  • Bin Li (45yo)

    Chief Executive Officer of Shanghai Emphasis Investment Management Consulting Co Ltd

    • Tenure: 4.2yrs

Board Members

  • James Hartono (43yo)

    Chairman & CEO

    • Tenure: 0yrs
    • Compensation: CN¥4.37m
  • Ying Wang (58yo)

    Executive Director

    • Tenure: 6.7yrs
    • Compensation: CN¥2.00m
  • To Chan (60yo)

    Executive Director

    • Tenure: 7.7yrs
    • Compensation: CN¥1.89m
  • Hong Wang (44yo)

    CFO & Executive Director

    • Tenure: 7.7yrs
    • Compensation: CN¥988.00k
  • Yiming Hu (55yo)

    Independent Non-Executive Director

    • Tenure: 6.1yrs
    • Compensation: CN¥204.00k
  • Tirtamarta Karsono (71yo)

    Independent Non-Executive Director

    • Tenure: 6.1yrs
    • Compensation: CN¥204.00k
  • Liky Sutikno (44yo)

    Independent Non-Executive Director

    • Tenure: 6.1yrs
    • Compensation: CN¥204.00k
  • Chung Chan (43yo)

    COO & Executive Director

    • Tenure: 3.8yrs
    • Compensation: CN¥2.28m

Company Information

Yestar Healthcare Holdings Company Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Yestar Healthcare Holdings Company Limited
  • Ticker: 2393
  • Exchange: SEHK
  • Founded: 1971
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: HK$3.427b
  • Shares outstanding: 2.38b
  • Website: https://www.yestarcorp.com

Number of Employees


Location

  • Yestar Healthcare Holdings Company Limited
  • Green Land Building
  • Floor 8, Block A
  • Shanghai
  • 201199
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2393SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDOct 2013

Biography

Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products; distribution of in vitro diagnostic products; and  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 12:53
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)